IL-4 bone therapy
US5714146A · kind A · utility
Assignee
Inventors
Key dates
| Filing date | Apr 7, 1995 |
| Grant date | Feb 3, 1998 |
| Priority date | — |
| Expiry date | Apr 7, 2015 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA01K2267/03
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
An in vivo assay for selecting a candidate therapeutic for treating osteoporosis. A candidate reagent is administered to an IL-4 transgenic mammal whose cells contain a recombinant IL-4 coding sequence operably lined to a promoter sequence which is transcriptionally active in bone marrow cells. At the time the candidate reagent is first administered the IL-4 transgenic mammal is either symptomatic of, or asymptomatic of, an osteoporotic phenotype. The candidate reagent is selected as a candidate therapeutic for treating osteoporosis if either amelioration of, or delay in the onset of, the osteoporotic phenotype is observed following administration of the candidate reagent to the IL-4 transgenic mammal.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.